Extract
Pulmonary arterial hypertension (PAH) is a sexually dimorphic disease that affects women more than men. Several pre-clinical and clinical studies identified 17β-oestradiol (E2), the most abundant female sex hormone, and/or its metabolite 16α-hydroxyoestrone as disease mediators in PAH (reviewed by Lahm et al. [1], and Foderaro and Venteuolo [2]). A recent case–control study even demonstrated significantly higher levels of E2 in men with PAH compared to controls [3].
Abstract
Inhibition of oestrogen signalling in PAH is currently being studied clinically but several questions remain http://ow.ly/G7xK30cPN5M
Footnotes
Support statement: This work was supported by US Dept of Veterans Affairs Merit Award 1I01BX002042-01A2 (to T. Lahm). Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received May 13, 2017.
- Accepted May 15, 2017.
- Copyright ©ERS 2017